SPARTAN: Interim analysis of first-line sparsentan in patients with IgAN
In this medfyle
IgAN is progressive disease and the most common form of primary glomerulonephritis, but treatment choice remains challenging. Sparsentan is a non-immunosuppressive DEARA that targets glomerular injury and slows kidney function decline. New data from 12 patients in SPARTAN suggest rapid and sustained reductions in proteinuria, as well as anti-inflammatory effects.
About this Medfyle
©2024 Infomedica-Medfyle. All rights reserved.
Source: Sparsentan (SPAR) as First-Line Treatment of Incident Patients with IgA Nephropathy: Interim Analysis of the SPARTAN Trial. Cheung CK, et al. Presented at Kidney Week 2024; #FR-OR63.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
